vs
EXACT SCIENCES CORP（EXAS）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.0B vs $878.4M），越洋钻探净利率更高（2.4% vs -9.8%，领先12.2%），EXACT SCIENCES CORP同比增速更快（23.1% vs 9.6%），越洋钻探自由现金流更多（$321.0M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 16.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
EXAS vs RIG — 直观对比
营收规模更大
RIG
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出13.6%
9.6%
净利率更高
RIG
高出12.2%
-9.8%
自由现金流更多
RIG
多$200.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
16.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.0B |
| 净利润 | $-86.0M | $25.0M |
| 毛利率 | 70.1% | 42.0% |
| 营业利润率 | -9.4% | 23.0% |
| 净利率 | -9.8% | 2.4% |
| 营收同比 | 23.1% | 9.6% |
| 净利润同比 | 90.1% | 257.1% |
| 每股收益（稀释后） | $-0.45 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRIG
| Q4 25 | $878.4M | $1.0B | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $988.0M | ||
| Q1 25 | $706.8M | $906.0M | ||
| Q4 24 | $713.4M | $952.0M | ||
| Q3 24 | $708.7M | $948.0M | ||
| Q2 24 | $699.3M | $861.0M | ||
| Q1 24 | $637.5M | $763.0M |
净利润EXASRIG
| Q4 25 | $-86.0M | $25.0M | ||
| Q3 25 | $-19.6M | $-1.9B | ||
| Q2 25 | $-1.2M | $-938.0M | ||
| Q1 25 | $-101.2M | $-79.0M | ||
| Q4 24 | $-864.6M | $7.0M | ||
| Q3 24 | $-38.2M | $-494.0M | ||
| Q2 24 | $-15.8M | $-123.0M | ||
| Q1 24 | $-110.2M | $98.0M |
毛利率EXASRIG
| Q4 25 | 70.1% | 42.0% | ||
| Q3 25 | 68.6% | 43.2% | ||
| Q2 25 | 69.3% | 39.4% | ||
| Q1 25 | 70.8% | 31.8% | ||
| Q4 24 | 69.0% | 39.2% | ||
| Q3 24 | 69.4% | 40.6% | ||
| Q2 24 | 69.8% | 38.0% | ||
| Q1 24 | 70.0% | 31.5% |
营业利润率EXASRIG
| Q4 25 | -9.4% | 23.0% | ||
| Q3 25 | -3.0% | -163.1% | ||
| Q2 25 | -0.3% | -97.6% | ||
| Q1 25 | -13.6% | 7.1% | ||
| Q4 24 | -122.8% | 13.7% | ||
| Q3 24 | -5.6% | -51.2% | ||
| Q2 24 | -3.8% | -6.9% | ||
| Q1 24 | -16.7% | -0.4% |
净利率EXASRIG
| Q4 25 | -9.8% | 2.4% | ||
| Q3 25 | -2.3% | -187.1% | ||
| Q2 25 | -0.1% | -94.9% | ||
| Q1 25 | -14.3% | -8.7% | ||
| Q4 24 | -121.2% | 0.7% | ||
| Q3 24 | -5.4% | -52.1% | ||
| Q2 24 | -2.3% | -14.3% | ||
| Q1 24 | -17.3% | 12.8% |
每股收益（稀释后）EXASRIG
| Q4 25 | $-0.45 | $0.13 | ||
| Q3 25 | $-0.10 | $-2.00 | ||
| Q2 25 | $-0.01 | $-1.06 | ||
| Q1 25 | $-0.54 | $-0.11 | ||
| Q4 24 | $-4.69 | $-0.14 | ||
| Q3 24 | $-0.21 | $-0.58 | ||
| Q2 24 | $-0.09 | $-0.15 | ||
| Q1 24 | $-0.60 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $2.4B | $8.1B |
| 总资产 | $5.9B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资EXASRIG
| Q4 25 | $964.7M | $620.0M | ||
| Q3 25 | $1.0B | $833.0M | ||
| Q2 25 | $858.4M | $377.0M | ||
| Q1 25 | $786.2M | $263.0M | ||
| Q4 24 | $1.0B | $560.0M | ||
| Q3 24 | $1.0B | $435.0M | ||
| Q2 24 | $946.8M | $475.0M | ||
| Q1 24 | $652.1M | $446.0M |
总债务EXASRIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益EXASRIG
| Q4 25 | $2.4B | $8.1B | ||
| Q3 25 | $2.5B | $8.1B | ||
| Q2 25 | $2.5B | $9.4B | ||
| Q1 25 | $2.4B | $10.2B | ||
| Q4 24 | $2.4B | $10.3B | ||
| Q3 24 | $3.2B | $10.2B | ||
| Q2 24 | $3.2B | $10.7B | ||
| Q1 24 | $3.1B | $10.5B |
总资产EXASRIG
| Q4 25 | $5.9B | $15.6B | ||
| Q3 25 | $5.9B | $16.2B | ||
| Q2 25 | $5.8B | $17.8B | ||
| Q1 25 | $5.7B | $19.0B | ||
| Q4 24 | $5.9B | $19.4B | ||
| Q3 24 | $6.7B | $19.5B | ||
| Q2 24 | $6.7B | $20.3B | ||
| Q1 24 | $6.4B | $19.9B |
负债/权益比EXASRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $321.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 30.8% |
| 资本支出强度资本支出/营收 | 3.6% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $626.0M |
8季度趋势，按日历期对齐
经营现金流EXASRIG
| Q4 25 | $151.7M | $349.0M | ||
| Q3 25 | $219.9M | $246.0M | ||
| Q2 25 | $89.0M | $128.0M | ||
| Q1 25 | $30.8M | $26.0M | ||
| Q4 24 | $47.1M | $206.0M | ||
| Q3 24 | $138.7M | $194.0M | ||
| Q2 24 | $107.1M | $133.0M | ||
| Q1 24 | $-82.3M | $-86.0M |
自由现金流EXASRIG
| Q4 25 | $120.4M | $321.0M | ||
| Q3 25 | $190.0M | $235.0M | ||
| Q2 25 | $46.7M | $104.0M | ||
| Q1 25 | $-365.0K | $-34.0M | ||
| Q4 24 | $10.7M | $177.0M | ||
| Q3 24 | $112.6M | $136.0M | ||
| Q2 24 | $71.2M | $49.0M | ||
| Q1 24 | $-120.0M | $-169.0M |
自由现金流率EXASRIG
| Q4 25 | 13.7% | 30.8% | ||
| Q3 25 | 22.3% | 22.9% | ||
| Q2 25 | 5.8% | 10.5% | ||
| Q1 25 | -0.1% | -3.8% | ||
| Q4 24 | 1.5% | 18.6% | ||
| Q3 24 | 15.9% | 14.3% | ||
| Q2 24 | 10.2% | 5.7% | ||
| Q1 24 | -18.8% | -22.1% |
资本支出强度EXASRIG
| Q4 25 | 3.6% | 2.7% | ||
| Q3 25 | 3.5% | 1.1% | ||
| Q2 25 | 5.2% | 2.4% | ||
| Q1 25 | 4.4% | 6.6% | ||
| Q4 24 | 5.1% | 3.0% | ||
| Q3 24 | 3.7% | 6.1% | ||
| Q2 24 | 5.1% | 9.8% | ||
| Q1 24 | 5.9% | 10.9% |
现金转化率EXASRIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
